Research articlePublished 8 Apr 2022
Ivermectin for Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis of Randomised Controlled Trials with Trial Sequential Analysis
1Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Queenstown, Singapore; 2Department of Intensive Care Medicine, Peninsula Health, Frankston, Victoria, Australia; 3Department of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia; 4Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Queenstown, Singapore; 5Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia; 6University of Queensland, Queensland University of Technology Brisbane and Bond University, Gold Coast, Queensland, Australia; 7Cardiothoracic Intensive Care Unit, National University Heart Centre, National University Hospital, Queenstown, Singapore
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Studies evaluating the effectiveness of ivermectin in reducing time to recovery in patients with COVID-19 have yielded mixed results. We conducted a systematic review and meta-analysis to determine if ivermectin was effective in patients with COVID-19. Methods: Six databases were searched for Randomised Controlled Trials (RCTs), assessing ivermectin in adults hospitalised with COVID-19 up till December 15th, 2021. Random effects meta-analyses (DerSimonian and Laird) were conducted. The risk of bias was evaluated using the Cochrane Risk-ofBias 2 tool, with certainty of evidence rated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. Trial sequential analysis (TSA) was conducted on the reduction in time-to-recovery, as well as mortality. Results: Twenty-three RCTs (3087 patients, 1601 ivermectin and 1486 control) were included in the meta-analysis; 5 with high risk of bias, 13 with moderate risk and 5 with low risk. Ivermectin reduced overall time-to-recovery (Hedges’ g: -0.65, 95%-CI: -1.04 to -0.27, p=0.0009, low certainty), and inhospital mortality (Risk Ratio [RR]: 0.62, 95%-CI: 0.39-0.99, p=0.046, low certainty). There were no differences in hospital length of stay (Hedges’ g: -0.49, 95%-CI: -1.16 to 0.18, p=0.15, low certainty), or the final proportion of patients with negative SARS-CoV-2 PCR (RR: 1.04, 95%-CI: 0.98-1.10, p=0.18, low certainty). TSA found that the cumulative Z-curve passed the TSA-adjusted boundary for benefit for time to recovery. The cumulative Z-curve did not pass the boundaries for benefit or futility for reduction in mortality. Conclusion: Our meta-analysis revealed ivermectin may reduce time-to-recovery in patients with COVID-19. However, most RCTs included were limited by risk of bias in the randomisation process, reporting of outcomes and deviations from intended interventions. There was also significant heterogeneity in terms of timing, duration, and dosing of ivermectin. Thus, the apparent benefit seen in this analysis should be interpreted in this context.
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Infectious Diseases & Therapy
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Christopher Jer Wei Low”
- BylineArticles whose byline prints “Ryan Ruiyang Ling”
- BylineArticles whose byline prints “Gabriel Yiqin Tham”
- BylineArticles whose byline prints “Ashwin Subramaniam”
- BylineArticles whose byline prints “Bee Choo Tai”
- BylineArticles whose byline prints “Kiran Shekar”
- BylineArticles whose byline prints “Kollengode Ramanathan”